BMC Cancer · 2021 · 18 citations · 20 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-based ImmunotherapyCytokines In Tumor ImmunityDendritic Cell BiologyTumor-associated AntigensCtla-4 InhibitionCtla-4 SignalingCytotoxic T Lymphocyte - Associated Protein 4 PathwayCytotoxic T Lymphocyte Antigen 4Cytotoxic T-lymphocyte Antigen 4 (Ctla-4) PathwayCytotoxic T-lymphocyte Antigen 4 SignalingDendritic Cell Cytokine ProductionDendritic Cell Signaling
BACKGROUND: Cytokine-induced killer cells induced with tumor antigen-pulsed dendritic cells (DC-CIK) immunotherapy is a promising strategy for the treatment of malignant tumors. However, itsefficacy isrestricted by the immunosuppression, which is mediated by the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathway. In order to overcome the negative co-stimulation from these T cells,we screened a nanobody targeted for CTLA-4 (Nb36) and blocked the CTLA-4 signaling with Nb36. METHODS: Peripheral blood mononuclear cells (PBMCs) were collected from healthy donors to beused to induce CIK cells in vitro, after which they were co-cultured with DC cells that had received tumor antigens. In addition, wetested whether blocking CTLA-4 signaling with Nb36 could promote in vitro DC-CIK cells proliferation, pro-inflammatory cytokine production and cytotoxicity,or not. For the in vivo experiments, we constructed a subcutaneously transplanted tumor model and placed it in NOD/SCID mice to verify the anti-tumor effect of this therapy. RESULTS: After stimulation with Nb36, the DC-CIK cells presented enhanced proliferation and production of IFN-γ in vitro, which strengthened the killing effect on the tumor cells. For the in vivo experiments, it was found that Nb36-treated DC-CIK cells significantly inhibited the growth of subcutaneously transplanted livercancer tumors, as well as reduced the tumor weight and prolonged the survival of tumor-bearing NOD/SCID mice. CONCLUSIONS: Ourfindings demonstrated that in response to CTLA-4 specific nanobody stimulation, DC-CIK cells exhibited a better anti-tumor effect. In fact, this Nb-based CTLA-4 blocking strategy achieved an anti-tumor efficacy close to that of monoclonal antibodies. Our findings suggest that DC-CIK cells + Nb36 have the potential totreatmalignant tumors through in vivo adoptive therapy.
20
Naturally occurring antibodies devoid of light chains
C. Hamers‐Casterman, T. Atarhouch, Serge Muyldermans et al. · Nature · 1993 · 3.2K citations
Pharmacy, Biochemistry, Immunology +14
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · Immunity · 1994 · 2.2K citations
A new member of the immunoglobulin superfamily—CTLA-4
Jean‐François Brunet, François Denizot, Marie‐Françoise Luciani et al. · Nature · 1987 · 1.3K citations